glp 1 example drugs How GLP-1 medications are transforming diabetes and weight loss treatment Mapping the effectiveness and risks

Nonarteritic anterior ischaemic optic neuropathy ( NAION ) is a sudden, painless cause of vision loss that occurs mainly in individuals with T2D

The FDA is currently evaluating whether GLP-1 medications may increase the risk of suicidal thoughts or actions

Because NAION and other optic nerve disorders can occur in patients with preexisting vascular risk factors, medical documentation is often necessary to assess causation and rule out alternative explanations

ANZCA have also established a dedicated webpage for GLP-1 receptor agonists - clinical practice recommendations which includes links to: The guidance document Clinical Practice Recommendations regarding patients taking GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists prior to anaesthesia or sedation for surgical and endoscopic procedures

Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS

The result is a lot of noise and not much clarity even among clinicians